241 related articles for article (PubMed ID: 21190978)
1. Mitogen-inducible gene-6 is a multifunctional adaptor protein with tumor suppressor-like activity in papillary thyroid cancer.
Lin CI; Du J; Shen WT; Whang EE; Donner DB; Griff N; He F; Moore FD; Clark OH; Ruan DT
J Clin Endocrinol Metab; 2011 Mar; 96(3):E554-65. PubMed ID: 21190978
[TBL] [Abstract][Full Text] [Related]
2. Thyroid-specific knockout of the tumor suppressor mitogen-inducible gene 6 activates epidermal growth factor receptor signaling pathways and suppresses nuclear factor-κB activity.
Lin CI; Barletta JA; Nehs MA; Morris ZS; Donner DB; Whang EE; Jeong JW; Kimura S; Moore FD; Ruan DT
Surgery; 2011 Dec; 150(6):1295-302. PubMed ID: 22136853
[TBL] [Abstract][Full Text] [Related]
3. LDOC1 inhibits proliferation and promotes apoptosis by repressing NF-κB activation in papillary thyroid carcinoma.
Zhao S; Wang Q; Li Z; Ma X; Wu L; Ji H; Qin G
J Exp Clin Cancer Res; 2015 Dec; 34():146. PubMed ID: 26637328
[TBL] [Abstract][Full Text] [Related]
4. Mitogen-inducible gene-6 expression correlates with survival and is an independent predictor of recurrence in BRAF(V600E) positive papillary thyroid cancers.
Ruan DT; Warren RS; Moalem J; Chung KW; Griffin AC; Shen W; Duh QY; Nakakura E; Donner DB; Khanafshar E; Weng J; Clark OH; Kebebew E
Surgery; 2008 Dec; 144(6):908-13; discussion 913-4. PubMed ID: 19040996
[TBL] [Abstract][Full Text] [Related]
5. BRAF-activated LncRNA functions as a tumor suppressor in papillary thyroid cancer.
Liao T; Qu N; Shi RL; Guo K; Ma B; Cao YM; Xiang J; Lu ZW; Zhu YX; Li DS; Ji QH
Oncotarget; 2017 Jan; 8(1):238-247. PubMed ID: 27462868
[TBL] [Abstract][Full Text] [Related]
6. Mitogen-Inducible Gene-6 Mediates Feedback Inhibition from Mutated BRAF towards the Epidermal Growth Factor Receptor and Thereby Limits Malignant Transformation.
Milewska M; Romano D; Herrero A; Guerriero ML; Birtwistle M; Quehenberger F; Hatzl S; Kholodenko BN; Segatto O; Kolch W; Zebisch A
PLoS One; 2015; 10(6):e0129859. PubMed ID: 26065894
[TBL] [Abstract][Full Text] [Related]
7. Quantitative assessment of RASSF1A methylation as a putative molecular marker in papillary thyroid carcinoma.
Kunstman JW; Korah R; Healy JM; Prasad M; Carling T
Surgery; 2013 Dec; 154(6):1255-61; discussion 1261-2. PubMed ID: 24383114
[TBL] [Abstract][Full Text] [Related]
8. Association of aberrant methylation of tumor suppressor genes with tumor aggressiveness and BRAF mutation in papillary thyroid cancer.
Hu S; Liu D; Tufano RP; Carson KA; Rosenbaum E; Cohen Y; Holt EH; Kiseljak-Vassiliades K; Rhoden KJ; Tolaney S; Condouris S; Tallini G; Westra WH; Umbricht CB; Zeiger MA; Califano JA; Vasko V; Xing M
Int J Cancer; 2006 Nov; 119(10):2322-9. PubMed ID: 16858683
[TBL] [Abstract][Full Text] [Related]
9. MiR-20b Displays Tumor-Suppressor Functions in Papillary Thyroid Carcinoma by Regulating the MAPK/ERK Signaling Pathway.
Hong S; Yu S; Li J; Yin Y; Liu Y; Zhang Q; Guan H; Li Y; Xiao H
Thyroid; 2016 Dec; 26(12):1733-1743. PubMed ID: 27717302
[TBL] [Abstract][Full Text] [Related]
10. BRAFV600E and RET/PTC Promote Proliferation and Migration of Papillary Thyroid Carcinoma Cells In Vitro by Regulating Nuclear Factor-κB.
Zhou D; Li Z; Bai X
Med Sci Monit; 2017 Nov; 23():5321-5329. PubMed ID: 29117154
[TBL] [Abstract][Full Text] [Related]
11. Aberrant hypermethylation of the HOXD10 gene in papillary thyroid cancer with BRAFV600E mutation.
Cao YM; Gu J; Zhang YS; Wei WJ; Qu N; Wen D; Liao T; Shi RL; Zhang L; Ji QH; Wang Y; Sun GH; Zhao YX; Wang YJ; Yu J; Zhu YX
Oncol Rep; 2018 Jan; 39(1):338-348. PubMed ID: 29115628
[TBL] [Abstract][Full Text] [Related]
12. MiR-577 inhibits papillary thyroid carcinoma cell proliferation, migration and invasion by targeting SphK2.
Xue KC; Hu DD; Zhao L; Li N; Shen HY
Eur Rev Med Pharmacol Sci; 2017 Oct; 21(17):3794-3800. PubMed ID: 28975989
[TBL] [Abstract][Full Text] [Related]
13. Low expression of Mig-6 is associated with poor survival outcome in NSCLC and inhibits cell apoptosis via ERK-mediated upregulation of Bcl-2.
Li Z; Qu L; Zhong H; Xu K; Qiu X; Wang E
Oncol Rep; 2014 Apr; 31(4):1707-14. PubMed ID: 24573418
[TBL] [Abstract][Full Text] [Related]
14. MicroRNA-146a targets PRKCE to modulate papillary thyroid tumor development.
Zhang X; Li D; Li M; Ye M; Ding L; Cai H; Fu D; Lv Z
Int J Cancer; 2014 Jan; 134(2):257-67. PubMed ID: 23457043
[TBL] [Abstract][Full Text] [Related]
15. Characterization of the novel tumor-suppressor gene CCDC67 in papillary thyroid carcinoma.
Yin DT; Xu J; Lei M; Li H; Wang Y; Liu Z; Zhou Y; Xing M
Oncotarget; 2016 Feb; 7(5):5830-41. PubMed ID: 26716505
[TBL] [Abstract][Full Text] [Related]
16. MiR-96-5p promotes the proliferation, invasion and metastasis of papillary thyroid carcinoma through down-regulating CCDC67.
Liu ZM; Wu ZY; Li WH; Wang LQ; Wan JN; Zhong Y
Eur Rev Med Pharmacol Sci; 2019 Apr; 23(8):3421-3430. PubMed ID: 31081096
[TBL] [Abstract][Full Text] [Related]
17. The BRAFV600E oncogene induces transforming growth factor beta secretion leading to sodium iodide symporter repression and increased malignancy in thyroid cancer.
Riesco-Eizaguirre G; Rodríguez I; De la Vieja A; Costamagna E; Carrasco N; Nistal M; Santisteban P
Cancer Res; 2009 Nov; 69(21):8317-25. PubMed ID: 19861538
[TBL] [Abstract][Full Text] [Related]
18. MiR-145 inhibits the migration and invasion of papillary thyroid carcinoma cells through NF-κB pathway regulation.
Chen G; Gao Y; Wang G; Dai G; Tong L
J Cell Biochem; 2020 Jun; 121(5-6):3325-3332. PubMed ID: 31907977
[TBL] [Abstract][Full Text] [Related]
19. Epigenetically upregulated WIPF1 plays a major role in BRAF V600E-promoted papillary thyroid cancer aggressiveness.
Zhang T; Shen X; Liu R; Zhu G; Bishop J; Xing M
Oncotarget; 2017 Jan; 8(1):900-914. PubMed ID: 27863429
[TBL] [Abstract][Full Text] [Related]
20. ZNRF3 is downregulated in papillary thyroid carcinoma and suppresses the proliferation and invasion of papillary thyroid cancer cells.
Qiu W; Yang Z; Fan Y; Zheng Q
Tumour Biol; 2016 Sep; 37(9):12665-12672. PubMed ID: 27448298
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]